Sensei Biotherapeutics To Present Initial Clinical Data From Dose Escalation Trial Of SNS-101 At 2023 SITC Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) will present initial safety and pharmacokinetic clinical data from its Phase 1/2 trial of SNS-101, a cancer therapy, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in November 2023. The presentation will focus on the safety, tolerability, and pharmacokinetics of SNS-101 as a monotherapy and in combination with cemiplimab in patients with advanced solid tumors.
October 25, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The presentation of initial clinical data from Sensei Biotherapeutics' Phase 1/2 trial of SNS-101 could potentially impact the company's stock positively, depending on the results.
The presentation of initial clinical data from a Phase 1/2 trial is a significant event for a biotech company like Sensei Biotherapeutics. Positive results could boost investor confidence and drive the stock price up, while negative or inconclusive results could have the opposite effect.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100